Telomir Pharmaceuticals (TELO) Projected to Post Quarterly Earnings on Wednesday

Posted by George Bondi on May 6th, 2026

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) will likely be issuing its results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01.

Telomir Pharmaceuticals Stock Performance

Shares of TELO opened at $1.33 on Wednesday. Telomir Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $3.10. The business’s 50 day moving average price is $1.32 and its two-hundred day moving average price is $1.34. The firm has a market cap of $45.73 million, a PE ratio of -4.03 and a beta of -0.21.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of institutional investors have recently modified their holdings of TELO. Bank of America Corp DE raised its position in shares of Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after purchasing an additional 10,880 shares during the period. Marshall Wace LLP acquired a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $95,000. Qube Research & Technologies Ltd acquired a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $33,000. Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $62,000. Finally, Raymond James Financial Inc. raised its position in shares of Telomir Pharmaceuticals by 4,101.9% during the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after purchasing an additional 73,547 shares during the period.

Wall Street Analyst Weigh In

TELO has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen raised Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating on the stock. Finally, Zacks Research raised Telomir Pharmaceuticals to a “hold” rating in a research report on Wednesday, March 18th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Check Out Our Latest Stock Report on TELO

About Telomir Pharmaceuticals

(Get Free Report)

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.